The potential clinical impact of miR-19b in LARC was hypothesized based on its regulatory function over the PP2A regulatory subunit PPP2R5E [26], whose alteration was previously described as a molecular mechanism to inhibit PP2A in CRC [42]. This evidence concerns the gene PTPA and colorectal carcinoma.